Vericel (VCEL) Q1 2025: Macy-Arthro Surgeons Drive 30%+ Biopsy Growth, Setting Up Back-Half Acceleration
Vericel’s Q1 2025 results reveal a business in transition, with Macy-Arthro surgeon training fueling a sharp increase in biopsies and signaling a likely inflection in implant volumes later this year. While burn care revenue was mixed, early Q2 indicators point to a rebound, and management’s raised margin outlook underscores confidence in operational leverage. Investors should watch the cadence of Macy conversion and Salesforce expansion as key levers for sustained double-digit growth into 2026.
Summary
- Macy-Arthro Training Delivers: Over 400 surgeons trained, driving biopsy growth above 30% among this cohort.
- Burn Care Volatility Persists: EpiCell revenue lagged, but Q2 graft activity is already outpacing Q1 volumes.
- Margin Guidance Raised: Improved gross and EBITDA margin targets reflect confidence in revenue mix and cost control.
Performance Analysis
Vericel delivered record Q1 revenue, anchored by Macy’s 15% YoY growth and robust early traction for the Macy-Arthro launch. The company’s $52.6 million in total net revenue was split across Macy ($46.3 million, 88% of total), EpiCell ($5 million), and Nexabrid ($1.3 million), with Macy’s performance matching historical seasonality but showing underlying acceleration in biopsy activity. Nexabrid, enzymatic debridement for burns, posted 207% YoY growth, though from a small base, while EpiCell, autologous skin grafts, saw revenue softness due to a spike in case cancellations and lower grafts per patient.
Gross margin held steady at 69% despite product mix headwinds, and operating expenses increased as planned due to headcount and facility investments. The company posted a net loss of $11.2 million, but generated $6.6 million in operating cash flow and ended the quarter with $162 million in cash and no debt, reinforcing a strong balance sheet. Management expects Q2 to mark a sharp step-up in both revenue and margin, driven by Macy implant conversion and EpiCell recovery.
- Biopsy Surge as Leading Indicator: Double-digit biopsy growth and a record number of trained Macy-Arthro surgeons set the stage for future implant revenue acceleration.
- Nexabrid Penetration Progressing: Consistent ordering centers and higher units per order signal deepening adoption, though overall revenue contribution remains modest.
- Q1 Margin Drag from EpiCell: Lower EpiCell revenue compressed gross margin, but management expects a reversal as Q2 volumes rebound.
The key to back-half growth will be biopsy-to-implant conversion, as the typical 4–6 month lag means Q1 biopsy strength will begin to impact Macy revenue in Q3 and beyond. Margin leverage is expected as high-fixed-cost infrastructure is absorbed over a larger revenue base, especially as EpiCell and Nexabrid scale.
Executive Commentary
"We’re very encouraged by the significant strength in both the underlying Macy business fundamentals and the early Macy-Arthro leading indicators, which point to potential opportunities for incremental Macy utilization in surgeon and patient segments across the Macy addressable market."
Nick Colangelo, President and Chief Executive Officer
"Gross profit for the quarter was $36.3 million, or 69% of net revenue, in line with the prior year gross margin of 69%, despite the lower EPICEL revenue... we expect margins to be significantly higher in the second quarter."
Joe Marra, Chief Financial Officer
Strategic Positioning
1. Macy-Arthro as a Growth Engine
Macy-Arthro, a minimally invasive cartilage repair instrument set, is catalyzing new biopsy activity and surgeon engagement. With approximately 400 surgeons trained by April, this cohort is delivering biopsy growth above 30%, notably among surgeons previously focused on patella cases. Importantly, the tool’s utility is expanding into trochlea and femoral condyle defects, broadening the total addressable market and unlocking new patient segments. Management expects this to drive hundreds of incremental biopsies and, as conversion lags resolve, a step-change in Macy implant volumes by late 2025 and into 2026.
2. Burn Care Franchise: Recovery and Cross-Sell
Nexabrid demonstrated sequential and YoY growth as ordering centers increase consistency and order size, but EpiCell’s Q1 revenue was hampered by patient health-related case cancellations. Early Q2 graft activity is already outpacing all of Q1, suggesting the shortfall was timing-related rather than structural. The cross-trained burn care Salesforce is beginning to unlock biopsies from previously dormant accounts, with a strategic goal of converting all accounts into dual EpiCell and Nexabrid users.
3. Margin Expansion and Cost Structure Discipline
Vericel raised its full-year gross margin guidance to 75% and adjusted EBITDA margin to 26%, reflecting confidence in higher-margin Macy growth, cost discipline, and minimal tariff exposure. The company’s US-based manufacturing and domestic sales base insulate it from current and potential future pharmaceutical tariffs, and operating expenses are expected to remain stable even as the Macy Salesforce expands in the second half.
4. Pipeline and Capacity Investments
The Macy Ankle development program remains on track for a Phase III study in H2 2025, targeting a $1 billion addressable market and future orthopedic expansion. The new manufacturing facility is set to begin commercial Macy production next year, supporting both scale and margin ambitions.
Key Considerations
Vericel’s Q1 marks a pivotal period where leading indicators for Macy-Arthro adoption are outpacing revenue, creating a setup for acceleration in the back half of the year and into 2026. Execution on Salesforce expansion, biopsy conversion, and burn care cross-sell will determine whether these early signals translate into durable double-digit growth.
Key Considerations:
- Surgeon Engagement Momentum: Over 400 Macy-Arthro trained surgeons already represent a meaningful share of the user base, with biopsy rates well above average.
- Addressable Market Expansion: Trochlea and femoral condyle cases are expanding Macy’s market beyond patella-focused segments.
- Salesforce Scaling: Targeted Salesforce expansion in H2 aims to support anticipated growth, focusing on high-volume territories without near-term disruption.
- Burn Care Variability: EpiCell’s revenue remains volatile, but cross-sell opportunities and Q2 biopsy activity suggest a near-term rebound.
- Cash Flow and Balance Sheet Strength: $162 million in cash and no debt provide ample flexibility for pipeline investment and commercial scaling.
Risks
Key risks center on the timing and magnitude of biopsy-to-implant conversion, as a failure to translate early biopsy momentum into implant revenue could undermine the Macy growth narrative. Burn care remains exposed to patient health variability and procedure timing, driving quarterly volatility. While tariff risk is minimal, any delay in Salesforce expansion or pipeline execution could temper the multi-year growth outlook. Investors should also monitor potential margin drag if EpiCell or Nexabrid underperform relative to Macy’s high-margin profile.
Forward Outlook
For Q2 2025, Vericel guided to:
- Total revenue of $64–66 million (22–25% growth)
- Macy revenue of approximately $54 million (22–24% growth)
- Gross margin in the low 70% range
- Adjusted EBITDA margin in the 20% range
For full-year 2025, management maintained revenue growth guidance of 20–23%, while raising:
- Gross margin guidance to 75%
- Adjusted EBITDA margin guidance to 26%
Management cited strong Q2 biopsy and graft activity, minimal tariff impact, and disciplined expense planning as key drivers. The Salesforce expansion is expected to begin in H2 2025, with the impact ramping into 2026.
- Implant conversion from Q1 biopsies will be a critical watchpoint for H2 revenue trajectory.
- Burn care franchise performance will be closely monitored for stability and cross-sell success.
Takeaways
Vericel’s Q1 sets the stage for a Macy-driven inflection, with biopsy growth and surgeon adoption outpacing near-term revenue but positioning the business for accelerated implant growth in the second half and 2026.
- Macy-Arthro is unlocking incremental biopsies and expanding the user base, creating a pipeline for future implant revenue that supports management’s bullish margin and growth guidance.
- Burn care remains lumpy, but early Q2 signals and Salesforce cross-training provide a path to more consistent contribution.
- Investors should monitor biopsy-to-implant conversion rates and Salesforce execution, as these will determine whether early indicators translate into sustained double-digit growth and margin expansion.
Conclusion
Vericel’s Q1 2025 results highlight a business at the cusp of an inflection, with Macy-Arthro adoption and strong leading indicators supporting a raised profitability outlook. Execution on Salesforce scaling and conversion will be critical to realizing the full potential of these early gains and sustaining the company’s growth trajectory into 2026 and beyond.
Industry Read-Through
Vericel’s experience with minimally invasive instrument launches and rapid surgeon upskilling offers a blueprint for medtech firms targeting procedure expansion through workflow simplification and training scale. The volatility in burn care revenue underscores the importance of patient mix and procedure timing for companies in acute care and biologics. Additionally, Vericel’s insulation from tariff risk highlights the strategic value of domestic manufacturing and supply chain control in an increasingly protectionist environment. Competitors and peers should note the impact of leading indicator tracking and Salesforce optimization as central levers for unlocking durable growth in procedure-driven markets.